<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Biostatistics</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E70EEAC4-A62E-4320-9A37-4D8FA670F93A"><gtr:id>E70EEAC4-A62E-4320-9A37-4D8FA670F93A</gtr:id><gtr:firstName>Anne</gtr:firstName><gtr:surname>Whitehead</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/45CD9A98-9C9A-4726-A5A7-5AE2558C283E"><gtr:id>45CD9A98-9C9A-4726-A5A7-5AE2558C283E</gtr:id><gtr:firstName>Andrea</gtr:firstName><gtr:otherNames>Lyn</gtr:otherNames><gtr:surname>Jorgensen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7AAC0F13-7669-495E-8826-6AAE0106F0D4"><gtr:id>7AAC0F13-7669-495E-8826-6AAE0106F0D4</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>Guy</gtr:otherNames><gtr:surname>Marson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9C45956A-2272-47ED-BADE-FBA5EEC51888"><gtr:id>9C45956A-2272-47ED-BADE-FBA5EEC51888</gtr:id><gtr:firstName>Dyfrig</gtr:firstName><gtr:otherNames>Arwyn</gtr:otherNames><gtr:surname>Hughes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/26F77E16-8B08-4A86-9A87-8CFCD60D0329"><gtr:id>26F77E16-8B08-4A86-9A87-8CFCD60D0329</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:surname>Dunn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/384E3C05-4352-42BC-B772-DE93B2BF713B"><gtr:id>384E3C05-4352-42BC-B772-DE93B2BF713B</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Roberts</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/85AB4A3B-4440-44C5-8065-7E9105C8B112"><gtr:id>85AB4A3B-4440-44C5-8065-7E9105C8B112</gtr:id><gtr:firstName>Carrol</gtr:firstName><gtr:surname>Gamble</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/150DF05A-FF1F-446E-86FD-4E68FCDA59C6"><gtr:id>150DF05A-FF1F-446E-86FD-4E68FCDA59C6</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Whitehead</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/77CC8C52-1D64-4172-B62E-6FBADDF7BF8F"><gtr:id>77CC8C52-1D64-4172-B62E-6FBADDF7BF8F</gtr:id><gtr:firstName>Catrin</gtr:firstName><gtr:surname>Tudur Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/57775794-FAE1-4C5E-BCA9-5D06A3F60E32"><gtr:id>57775794-FAE1-4C5E-BCA9-5D06A3F60E32</gtr:id><gtr:firstName>Bridget</gtr:firstName><gtr:surname>Young</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/87C69C86-BA76-4517-BF4C-25AB3ED45CE3"><gtr:id>87C69C86-BA76-4517-BF4C-25AB3ED45CE3</gtr:id><gtr:firstName>Shon</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Lewis</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E7E0FD44-2BF4-4517-AC8D-F13A255A0017"><gtr:id>E7E0FD44-2BF4-4517-AC8D-F13A255A0017</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Bower</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6E56F002-652C-455D-B118-0DD385AEAD03"><gtr:id>6E56F002-652C-455D-B118-0DD385AEAD03</gtr:id><gtr:firstName>Carlo</gtr:firstName><gtr:surname>Berzuini</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A8C83E28-6D54-494A-BF9D-5F51C0306BE1"><gtr:id>A8C83E28-6D54-494A-BF9D-5F51C0306BE1</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>Andrew</gtr:otherNames><gtr:surname>Emsley</gtr:surname><gtr:orcidId>0000-0002-1218-675X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9E500403-291B-4FE4-AB79-023730242F30"><gtr:id>9E500403-291B-4FE4-AB79-023730242F30</gtr:id><gtr:firstName>Iain</gtr:firstName><gtr:otherNames>Edward</gtr:otherNames><gtr:surname>Buchan</gtr:surname><gtr:orcidId>0000-0003-3392-1650</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/72DC2B63-8B96-4B63-84E1-52D775ED665D"><gtr:id>72DC2B63-8B96-4B63-84E1-52D775ED665D</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>W</gtr:otherNames><gtr:surname>Beresford</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/77F021F2-CB59-421B-9A71-664FE2218FBD"><gtr:id>77F021F2-CB59-421B-9A71-664FE2218FBD</gtr:id><gtr:firstName>Munir</gtr:firstName><gtr:surname>Pirmohamed</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C5D38AFF-0D8F-4D11-B91B-7954A21AF259"><gtr:id>C5D38AFF-0D8F-4D11-B91B-7954A21AF259</gtr:id><gtr:firstName>Paula</gtr:firstName><gtr:surname>Williamson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F766798C-C03F-4546-B715-7AC05C12738E"><gtr:id>F766798C-C03F-4546-B715-7AC05C12738E</gtr:id><gtr:firstName>Thomas</gtr:firstName><gtr:otherNames>Friedrich</gtr:otherNames><gtr:surname>Jaki</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK025635%2F1"><gtr:id>339D3B0C-5458-4A1A-BFF0-222174EF078F</gtr:id><gtr:title>MRC North West Hub for Trials Methodology Research</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K025635/1</gtr:grantReference><gtr:abstractText>The Medical Research Council funded North West Hub for Trials Methodology Research (NWHTMR) is a collaboration which brings together experts in clinical trials research from the Universities of Liverpool, Lancaster, Bangor and Manchester. Clinical trials are studies conducted in patients to evaluate the potential benefits (and risks) that new treatments could offer. They provide the 'gold standard' evidence base for informing and improving future patient care. The Hub has experts in medical statistics, clinical trials methods, pharmacoeconomics (drugs are compared for their value), sociology and clinical psychology. 

The Mission of the Hub is to create a world-class centre where methods used in clinical trials can be investigated. The overall aim is to improve patient care by making sure we test, use and develop the best methods possible for clinical trials. This will help to make sure that research studies are relevant and correctly measuring what we want to measure. The Hub also works in collaboration with patients and service users to make sure their experiences of clinical trials and health conditions are included in developing better methods for carrying out clinical trials. Together we are committed to making sure that the best methods possible to design, run and analyse clinical trials are researched, developed, used and further evaluated. 

The Hub focuses on four themes:
- Early phase trial design and analysis, (when drugs are first researched to check for their safety and to see what effect they have)
- Later phase trial design and analysis and (when drugs are checked to see how well they work in routine care)
- Patients' perspectives, (what patients' experiences of taking part in clinical trials are)
- Efficacy and mechanism evaluation of targeted therapies (choosing the right drug or drug dose to give to a patient, sometimes referred to as 'personalised medicine')

We want to make sure that we develop good methods that can be used in key clinical areas and we have a particular interest in drug safety, medicines for children, mental health, epilepsy, cancer, surgical trials and infection.

The major aims of the Hub are to:
- Provide a world-class environment for carrying out research that will improve the design, conduct and analysis of clinical trials; 
- Make sure that our findings are used to improve the methods used in future clinical trials. 
- Set up training programmes to develop the next generation of clinical trial experts.
- Work in partnership with others, both in the public sector and industry.

The key objectives are to: 
- Improve the design, conduct, analysis and reporting of clinical trials; 
- Develop a methodological research portfolio generated by a broad team of investigators from a range of disciplines; 
- Build on considerable local Cochrane expertise to improve the integration between trials and systematic reviews in relation to trial design and reporting; 
- Use local strengths in pharmacology (the study of drugs) to improve the design of drug clinical trials; 
- Train the next generation of clinical trials experts; 
- Work well with industry in developing good clinical trials; 
- Publicise the work that we have done. 

Key achievements to date include:
- The COMET (Core Outcome Measures in Effectiveness Trials) Initiative (www.comet-initiative.org) - this project works with international experts and patients interested in the development and application of agreed standardised sets of outcomes, known as 'core outcome sets'.
- The Database of Instruments for Resource Use Measurement (DIRUM www.dirum.org), (A bank of tested questionnaires for use by health economists)
- A network meeting &amp;quot;Improving accrual and recruitment conduct in clinical trials with children and other patients unable to consent for themselves&amp;quot; (http://www.liv.ac.uk/nwhtmr/events/past_events/recruit_meeting.htm.

Further details are available at http://www.liv.ac.uk/nwhtmr.</gtr:abstractText><gtr:technicalSummary>The Medical Research Council funded North West Hub for Trials Methodology Research (NWHTMR) is a collaborative centre which brings together experts in biostatistics, clinical trials methodology, pharmacoeconomics, sociology and clinical psychology from the Universities of Liverpool, Lancaster, Bangor and Manchester. Our mission is to create a world-class centre where methodological issues facing the clinical trials community can be investigated, the overall aim being to improve patient care by improving the validity and relevance of the healthcare evidence base.
 
The Hub has four major methodological themes as follows. 

(1) Early phase trial design and analysis
Early phase trials lend themselves to adaptive procedures which allow research to proceed in stages. Bayesian methods may be utilised, in which prior information is incorporated and updated by data as they accumulate. The objective of the research group is to develop, promote, and implement adaptive methods for early phase trials.

(2) Later phase trial design and analysis 
Later phase, or effectiveness trials, involve particular methodological issues. The objective of this theme is to address priority topics, for example the choice of outcomes important to patients and other decision-makers, and the identification of interventions to improve recruitment and retention of participants. 

(3) Patients' perspectives 
This theme is focussed on three workstreams: (i) optimising patient and public involvement in trials; (ii) ensuring patient centred and effective recruitment; (iii) incorporating patient priorities in outcome measurement.

(4) Efficacy and mechanism evaluation of targeted therapies
The idea that a given medical treatment will have more benefit for some patients than for others is the underlying foundation of what is termed personalised or stratified medicine. This group will develop trial designs for stratified medicine within which evaluation of mechanism is a key feature.</gtr:technicalSummary><gtr:potentialImpactText>Who will benefit from this research?

The cross-disciplinary nature of the Hub's research portfolio and partnerships will ensure that a wide range of users will benefit from this research, including clinical trial practitioners, systematic reviewers, patients and the public, regulators, research funders, journal editors, policymakers, and methodologists.

How will they benefit from this research? 

The Hub will facilitate the advancement of clinical trials methodology which will lead to improvements in, and increased efficiency of, clinical trials, leading to improvements in health care. Direct and indirect impacts for users include:

(1) Clinical trial practitioners 

Hub research will generate new knowledge and innovative methodologies which will be deliberately developed to be of relevance to clinical trial practitioners who will also benefit from the Hub's training activities. The Hub will deliver highly skilled researchers in priority, scarce, multi-disciplinary areas such as health informatics, medical statistics and health economics, that will directly benefit clinical trial practitioners through the hub's advisory service, and by developing this workforce for future clinical trials. 

(2) Systematic reviewers 

The Hub research and training programme that focusses on improving the conduct, analysis and reporting of clinical trials has the potential to directly improve the systematic review process (e.g. disseminating recommendations on outcome reporting to clinical trialists will reduce the important problem of outcome reporting bias in systematic reviews). The hub's research will also contribute to recommendations about how best to use systematic reviews to inform clinical trial design and conduct. 

(3) Patients and the public 

Through implementation of recommendations of the Theme 3 Patients' Perspectives Management Group regarding best practice in patient and public engagement, the hub will generate research that will directly impact upon participants of clinical trials (e.g. the hub's work on RECRUIT project) as well as the wider patient groups for which those trial results apply. Use of innovative, more appropriate, evidence-based methods in clinical trials will lead to trial results that are more applicable (e.g. using outcomes that are relevant to patients), which will improve clinical decisions and impact on patients' quality of life, health and well-being. 

(4) Research Funders 

The Hub has already achieved impact with funders as the NIHR HTA and HRB Ireland guidance documents for applicants now refer to the COMET database. In addition to direct impact such as this, many of the hub's activities include a focus upon improving efficiency of clinical trials and reducing 'waste', which will lead to more appropriate, targeted, use of resources and impact research funding bodies. 

(5) Journal editors 

Activities within the hub portfolio that focus on research to improve the reporting of clinical trials will be of direct benefit to journal editors. Hub members are involved with international groups such as the EQUATOR Network and CONSORT, and these links will be exploited to aid dissemination.

(6) Policymakers 

Through COMET we are learning how to engage with influential policymakers such as PCORI (US) and NICE (UK). Further impact is likely due to our ongoing work to compare outcomes selected for inclusion in NICE guidelines with existing core outcome sets.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2321030</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Association of Medical Research Charities, The COMET Initiative</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A293CFE1-19BA-4E3A-80EF-4BF99CF73B3B</gtr:id><gtr:impact>Raising awareness of core outcome sets and the work of the COMET initiative</gtr:impact><gtr:outcomeId>58ada342903085.64856099</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Third sector organisations</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Centre for Biostatistics, Melbourne, 26th November 2015 (RE)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E19A3C65-6B22-4464-91F3-5C7DDAA3C54D</gtr:id><gtr:impact>Dissemination of research and promotion of related papers</gtr:impact><gtr:outcomeId>56c33555bb3fd7.20872182</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 36th Society for Clinical Trials Conference 2015 (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EB03DBC9-C258-4A48-B72C-812535375DEB</gtr:id><gtr:impact>Raising profile of Hub; Dissemination of hub research


NA</gtr:impact><gtr:outcomeId>567a6631c426e7.27104844</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Trials methodology research workshop', Society for Clinical Trials, Montreal, May 2016 (PW)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>82CC510D-E4D6-42B9-BA67-0D99A47F380E</gtr:id><gtr:impact>Dissemination activity for trials methodology research in the UK.</gtr:impact><gtr:outcomeId>58a31a0e5e1a29.41524254</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 8th Annual optimising clinical trials summit (AHM)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4CB6A255-DCE8-4254-B8A5-9534F2302B35</gtr:id><gtr:impact>Dissemination of research

NA</gtr:impact><gtr:outcomeId>567a618765cdc7.37168512</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Factorial versus multi-arm multi-stage designs in clinical trials (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>25CA7850-5CE8-427E-A14D-8478F1594F29</gtr:id><gtr:impact>Dissemination of work</gtr:impact><gtr:outcomeId>58ac201aeaa321.21253755</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, NWHTMR Research day 'Improving Trials by Improving Trials for Patients' 2015 (PB)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B68E0477-74B2-4757-B2F7-7A6284F7A292</gtr:id><gtr:impact>Raising profile of NWHTMR</gtr:impact><gtr:outcomeId>567a62df1434b7.74584862</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 35th Conference of the International Society for Clinical Biostatistics 2014 (LH)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B4572AB4-F34E-4ACB-B5EA-14EEBA2B65E9</gtr:id><gtr:impact>Wider dissemination of work

None</gtr:impact><gtr:outcomeId>545cc26dc1c772.59791816</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, NWHTMR Research day 'Improving Trials by Improving Trials for Patients 2015 (BY)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>32E37930-81F6-4D93-AC07-650ABE244963</gtr:id><gtr:impact>Raising profile of NWHTMR</gtr:impact><gtr:outcomeId>567a64a374b124.33500009</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Optimal multi-arm multi-stage designs (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F4B0DDDA-4DD2-4196-8409-E32A2F237727</gtr:id><gtr:impact>Dissemination of work</gtr:impact><gtr:outcomeId>58ac1f11c5b835.80215847</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET VI conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EA2F8067-8BB0-4651-BFF3-3CEAA959A5A7</gtr:id><gtr:impact>Raising awareness of core outcome sets and the work of the COMET initiative</gtr:impact><gtr:outcomeId>58ad9f98c29251.87255908</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET Workshop, 23rd Cochrane Colloquium Vienna (LG)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>26A48F19-BFBC-4A44-90D4-81DF6DB75DA0</gtr:id><gtr:impact>A well attended workshop with good feedback</gtr:impact><gtr:outcomeId>56c336f5beae18.38957593</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>E-trials within the UKCRC CTU Network - opportunities and challenges (DA)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>43C968B2-F658-4D74-B487-D49BC081AB12</gtr:id><gtr:impact>Overview of E-Trials from a CTU Perspective</gtr:impact><gtr:outcomeId>58aab4f765efd7.73927468</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Development of a PKPD model of dual-therapy for gout to assess the impact of medication adherence on treatment success (DHM)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F6520364-645F-4A79-AC69-3383DBEE9B05</gtr:id><gtr:impact>Dissemination of work. No impact yet.</gtr:impact><gtr:outcomeId>58ac16952f79b0.50368520</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Federation of Pharmaceutical Industries and Associations (EFPIA), A Healthier Future: Enabling outcomes-driven sustainable healthcare</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A76CCA09-2E82-4948-8D1C-CB80B95EDB97</gtr:id><gtr:impact>Raising awareness of core outcome sets and the work of the COMET initiative</gtr:impact><gtr:outcomeId>58ada2356a4d70.09876258</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Improving Design, Evaluation and Analysis of Early Drug Development Studies (IDEAS) (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5D9D1E51-F4E5-46A6-88D3-FC55380E07C2</gtr:id><gtr:impact>Dissemination of work</gtr:impact><gtr:outcomeId>58ac1fc9bd5153.32065770</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Symposium on Early Phase Dose Finding Methodology 2015 (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0228C072-268C-40F1-8EB2-99D7980CA03F</gtr:id><gtr:impact>Raising profile of Hub; Dissemination of hub research


NA</gtr:impact><gtr:outcomeId>567a667dd7afb0.17168916</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Know what to know - Some guidance for efficient experimental and clinical study design (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>11B69383-150D-425C-8543-FB0AF175A38B</gtr:id><gtr:impact>Dissemination of work</gtr:impact><gtr:outcomeId>58ac1fec476be6.31924624</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Pfizer 2014 (DH)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>12D88359-6DFD-4ABD-95D3-B4C634B2B977</gtr:id><gtr:impact>Collaborator for studentship


None at present</gtr:impact><gtr:outcomeId>54607514852273.50424419</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, GlaxoSmithKline 2014 (DH)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D40203DA-2823-438C-A272-DC164526C706</gtr:id><gtr:impact>Planned progression to collaborative project


None at present</gtr:impact><gtr:outcomeId>546074ca46f996.57931095</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Oxford 2014 (PB)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FBB941D2-21E5-44B3-8B90-7A1DC062BB96</gtr:id><gtr:impact>Discussion

None at present</gtr:impact><gtr:outcomeId>545740865af873.75232100</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Health economics for stratified medicine (DH)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DE7557DE-ABA9-49F0-A4FD-2F7594F6A51B</gtr:id><gtr:impact>Dissemination of work. No impact yet.</gtr:impact><gtr:outcomeId>58ac16d5dada42.48799900</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinical Trial Design for Rare Diseases using Bayesian Bandit Models (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>920708CF-51CB-4017-A703-90923524D910</gtr:id><gtr:impact>Dissemination of work</gtr:impact><gtr:outcomeId>58ac1fa773c426.52605012</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 35th Conference of the International Society for Clinical Biostatistics 2014 (AC)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>769489D0-52C5-438F-AB8A-8789844878EE</gtr:id><gtr:impact>Wider dissemination of work


None at present</gtr:impact><gtr:outcomeId>54576f2484be14.78777425</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Economics of adherence (DH)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1DF98932-BBC9-42A9-971B-DBDF53472E99</gtr:id><gtr:impact>Dissemination of work. No impact yet.</gtr:impact><gtr:outcomeId>58ac19afdb3801.24764069</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET Workshop, Cochrane UK &amp; Ireland symposium 2015 (LG)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6E26A6A5-22D2-4664-BB1A-D573F4D9B930</gtr:id><gtr:impact>A well attended workshop with good feedback</gtr:impact><gtr:outcomeId>56c336b2cc0a22.34750009</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Generation R and the VOICES Project. RCPCH Annual Conference, Liverpool, UK, 28th April 2016 (KW)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>506FDD76-9D0A-4C34-9F36-DB4811CE301F</gtr:id><gtr:impact>To present the MRC funded VOICES project aims and design with a member of our VOICES young person's advisory group. Led to interesting discussion about how children and young people can be engaged in all stages of research and what it means to be a young person involved in research.</gtr:impact><gtr:outcomeId>58ad75c25f7ea9.42058642</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, CTMC Edinburgh 2014 (RE)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8D326713-0DE0-4771-9AFC-96AD9F1650F5</gtr:id><gtr:impact>Questions and discussion with other academics


Future research and publications planned</gtr:impact><gtr:outcomeId>5460760ec394f5.78901606</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International approaches to consent seeking in pediatric critical care trials: the views of parents and healthcare providers. The 8th World Congress of the World Federation of Pediatric Intensive &amp; Critical Care Societies (PICC), Toronto, Ontario, Canada, June 4-8 2016 (KW)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A6F82141-58E2-404F-B8C2-BAADCA51563F</gtr:id><gtr:impact>Poster to help engage international health care practitioners in our work around research without prior consent. Led to new connections/twitter followers.</gtr:impact><gtr:outcomeId>58ad74d101e0b2.66224835</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Institute of Population Health Postgraduate showcase 2014 (AHM)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9D4B5D82-2FB5-4CE0-8149-B0AC9AE0703E</gtr:id><gtr:impact>Discussion

Not aware of any notable impacts</gtr:impact><gtr:outcomeId>54588d9641ae42.08287575</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>A weighted differential entropy based approach for dose-escalation trials (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B816E237-B201-4155-9F90-61F63439DB09</gtr:id><gtr:impact>Dissemination of work</gtr:impact><gtr:outcomeId>58ac1f48924d26.16226521</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Institute Gustave-Roussy 2014 (LH)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>05CF6483-12D4-4F86-BDF0-E2D7F5DCE1C3</gtr:id><gtr:impact>Wider dissemination of work

Developed a collaboration with Dr Marie-Cecile Le Deley which has culminated in joint supervision of a PhD student who started in October 2014 and is developing novel Bayesian designs for clinical trials in rare cancers</gtr:impact><gtr:outcomeId>545cc1f497ab16.87248565</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, MRC/NIHR Methods Fellows Meeting 2014 (RE)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>241358F8-64B3-4619-8B3F-4BE64B55542B</gtr:id><gtr:impact>Discussion with audience about MRC career's options, and stratified medicine research


Collaboration with Newcastle around methodology work</gtr:impact><gtr:outcomeId>546076606edae8.08579124</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 5th Annual Summit for Clinical Ops Executives 2014 (AHM)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>96209341-3BD4-4473-BC7A-4D844B768995</gtr:id><gtr:impact>Dicussion

No notable impacts</gtr:impact><gtr:outcomeId>54588d324cce58.82933895</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Manchester 2014 (PB)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>601BF6B8-F4CC-4DDE-8970-07DD0B038696</gtr:id><gtr:impact>Education and training

Change in practice in attendants</gtr:impact><gtr:outcomeId>5457433a2de6f4.62624895</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cost-effectiveness of preventing medication errors (DH)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5C70CAEC-EAB2-4EF8-8C9C-E9606956BC2F</gtr:id><gtr:impact>Workshop presentation</gtr:impact><gtr:outcomeId>58ac192e0ccbc7.26181999</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, University of Newcastle 2015 (BY)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>72AD94AD-D6FB-4E63-817F-C7D0506C95FB</gtr:id><gtr:impact>Dissemination of Hub research particularly EPIC study</gtr:impact><gtr:outcomeId>567a64fd7bbea4.30092561</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Australian Biometric Society conference, Hobart, 1st December 2015 (RE)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BA0D5023-ACBE-4772-A7E8-D86CFA963F60</gtr:id><gtr:impact>Overview of research on stratified medicine</gtr:impact><gtr:outcomeId>56c3359ebed9d3.18937208</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Institute for Translational Medicine Research Day 2015 (AJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>02FEF93D-70EE-492D-921F-1BCDC4F2BA8F</gtr:id><gtr:impact>Increasing profile of research group of Hub network; initiating new collaborations with researchers</gtr:impact><gtr:outcomeId>56c3330bdf4f13.64555919</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Faculty for Oncology and Palliative Care Meeting 2014 (BY)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7C3045C7-D25D-4C0D-AB77-75140A4D703A</gtr:id><gtr:impact>Unknown at this point</gtr:impact><gtr:outcomeId>545b4f5ed802f3.96191627</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Prevention Science Methodology Group 2014 (RE)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>135F0296-3FCA-4326-8DFC-C386F367C6DD</gtr:id><gtr:impact>Interaction with international researchers in mediation analysis


Discussions about future publications</gtr:impact><gtr:outcomeId>546075b3d89bf3.97913118</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET workshop, Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, Australia, July 2016 (PW)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4D0780E5-2905-4B89-A7D3-829BD38758A4</gtr:id><gtr:impact>Workshop on core outcome sets presented.</gtr:impact><gtr:outcomeId>58a31925497e18.71859229</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Uncertainty and examples of reimbursement issues with accelerated release of drugs (DH)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E6DE5DCA-6669-4CC0-8361-B4694F149C52</gtr:id><gtr:impact>Workshop presentation</gtr:impact><gtr:outcomeId>58ac18c4049a79.98768609</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk NWHTMR Improving health by improving trials April 2014 (KW)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1519A2F3-F84F-4B27-A459-89A564A8EDF9</gtr:id><gtr:impact>Raising profile of Hub

NA</gtr:impact><gtr:outcomeId>568e2273517727.70608698</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Centre of Excellence for Public Health, Queen's University Belfast, 27th September 2015 (RE)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6CD45C4A-8D25-4233-B765-FA1021CEDFE0</gtr:id><gtr:impact>Overview of research on stratified medicine</gtr:impact><gtr:outcomeId>56c33475c0dcd1.86593052</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK parents report agreeing to paediatric intensive and critical care trial to help other children in the future. The 8th World Congress of the World Federation of Pediatric Intensive &amp; Critical Care Societies (PICC), Toronto, Ontario, Canada, 4-8th June 2016 (KW)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A7209950-9289-4148-ADE7-0ECFAC5F739F</gtr:id><gtr:impact>Poster to help engage international health care practitioners in our work around research without prior consent. Led to new connections/twitter followers.</gtr:impact><gtr:outcomeId>58ad7535162448.34960757</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Citation analysis: a new approach to assess the  uptake of core outcome sets? (KB)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4E85EA0A-D443-4F91-AB5E-E0A6917431A9</gtr:id><gtr:impact>Dissemination of work followed by questions.</gtr:impact><gtr:outcomeId>58a5c2891cb191.75433234</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PACT workshop, Manchester 2014 (PB)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F4070C37-FFBE-4E65-AB10-A0D64E351272</gtr:id><gtr:impact>20 participants knowledge exchange and identification of future methodological research to improve patient experience of trials

Links with INVOLVE</gtr:impact><gtr:outcomeId>545741f284d731.07468769</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Workshop, Nuffield Council on Bioethics 2014 (BY)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DD2A1698-9587-4555-ADE3-507811895A72</gtr:id><gtr:impact>Discussion of wide range of ethical, methodological, PPI and practical issues related to children's research worldwide

Nuffield Council report due April 2015</gtr:impact><gtr:outcomeId>545b519aa7f273.46197930</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, RCPCH Annual Conference 2015 (KW)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8FC94277-C625-4E98-BA56-21F8D8CD9B55</gtr:id><gtr:impact>Dissemination of CONNECT study guidance on deferred consent for critical care trials

NA</gtr:impact><gtr:outcomeId>567a642f91e2c1.02336398</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, SMi Conference on Adaptive designs in Clinical Trials 2014 (LH)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2B432BCA-6F9C-4C8F-BAE6-DAC6F377C7C1</gtr:id><gtr:impact>Wider dissemination of work to the pharmaceutical industry

None</gtr:impact><gtr:outcomeId>545cc1734cadb8.21813402</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Australian Pharmaceutical Biostatisticians Group, Sydney, 7th December 2015 (RE)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EB01CBC7-243C-45D7-A68C-56E94E13C913</gtr:id><gtr:impact>Overview of research on causal inference</gtr:impact><gtr:outcomeId>56c335de0db513.00255178</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 16th Annual J&amp;J Pharma Statistics Conference (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>11233DBA-B6ED-422E-B918-1642A3B396EB</gtr:id><gtr:impact>Wider dissemination of work


Discussions about implementation of method with Janssen Pharmaceutica</gtr:impact><gtr:outcomeId>545770814d4cd7.77085440</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Virtual Presentation to  HRB Trials Methodology Research Network 2015 (PB)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4911CB72-EAE0-4D78-AE50-1681D16B99AE</gtr:id><gtr:impact>Raising profile of NWHTMR</gtr:impact><gtr:outcomeId>567a634f89c4a1.43389459</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Workshop on methods for core outcome set development, London, January 2016 (PW)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2934C1DE-20DA-484E-A651-0D8D052A46BC</gtr:id><gtr:impact>Workshop to facilitate discussion on the methods to use when developing a core outcome set.</gtr:impact><gtr:outcomeId>58a31a5193c5f6.54049422</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Virtual Presentation to University of Edinburgh MSc in Clinical Trials 2015 (PB)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E5A87AF2-AFDD-4D34-8D1E-FCB8E3EBC8C7</gtr:id><gtr:impact>Raising profile of NWHTMR and learning for students

Raising profile of NWHTMR</gtr:impact><gtr:outcomeId>567a63b5769181.42789630</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 35th Conference of the International Society for Clinical Biostatistics 2014 (WYY)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F804CBB3-3D38-4BAD-84E9-1817E8429456</gtr:id><gtr:impact>Wider dissemination of work


None at present</gtr:impact><gtr:outcomeId>54576f61ebce75.80505049</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Children and young people support research without prior consent in life threatening situations: a qualitative study. European Academy of Paediatric Societies (EAPS), Geneva, Switzerland, 21st-25th October 2016 (KW)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>40D4670A-CDDD-4A9C-AD42-70BE3C41570D</gtr:id><gtr:impact>To show how children and young people support research without prior consent and encourage practitioners to engage children in critical care trial research discussions. This sparked discussion and interest in the CONNECT guidance on research without consent and showed support for the creation of an animation to help practitioners and parents inform and engage children in critical care trial discussions.</gtr:impact><gtr:outcomeId>58ad743a4df570.21220345</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, ICTMC, Glasgow, 17th November 2015 (RE)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2B7E5572-DF50-430D-8BA1-D001B850EBBB</gtr:id><gtr:impact>Dissemination of latest findings of NWHTMR Theme 4 research</gtr:impact><gtr:outcomeId>56c336342b3ed0.78364320</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Aberdeen 2014 (PB)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BD7110F0-23C4-42E4-9635-93161B500916</gtr:id><gtr:impact>Discussion

None at present</gtr:impact><gtr:outcomeId>545741373afec9.95570107</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, HTMR Network Meeting, Bristol, 27th January 2015 (RE)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>844BDF20-18B1-4B20-A05C-FB6FA53EA4BC</gtr:id><gtr:impact>Overview of research on stratified medicine</gtr:impact><gtr:outcomeId>56c333b0f38b43.11736637</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Health economics for stratified medicine (2) DH</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ACEF443E-86E1-4CEC-BA5B-3D836B3C0A2E</gtr:id><gtr:impact>Dissemination of work. No impact yet.</gtr:impact><gtr:outcomeId>58ac17379be647.38256250</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Weighting clinical trial outcomes by patients' preferences: a case study in epilepsy (EH)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E951B500-BF15-402D-B4E2-B3270D6A87D3</gtr:id><gtr:impact>Dissemination of work. No impact yet.</gtr:impact><gtr:outcomeId>58ac1add3bfc24.23073965</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, British  Society for Hematology 2015 (AJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>47361F0A-F937-4625-A7B3-E7B0C9E69355</gtr:id><gtr:impact>Dissemination of findings of EU-PACT, a biomarker guided trial</gtr:impact><gtr:outcomeId>56c33363161a40.34263615</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 35th Conference of the International Society for Clinical Biostatistics (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9CD75A87-63D3-4B13-829D-4C25BA3B2483</gtr:id><gtr:impact>Wider dissemination of work


Discussions about implementation of method with a CRO</gtr:impact><gtr:outcomeId>54576fc79a2598.82864412</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Mini Symposium on alternative methods for dose-finding and dose-ranging trials 2015 (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9ECD6262-C0AF-47E6-9B40-2571BF2E8B71</gtr:id><gtr:impact>Raising profile of Hub; Dissemination of hub research


Has led to Merck adopting a model based approach to dose finding for the first time</gtr:impact><gtr:outcomeId>567a66d87e3568.21427966</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Novartis internal statistics seminar series 2014 (SS)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7B4C110D-EEF0-4B1F-9E22-5418086B9AB7</gtr:id><gtr:impact>Wider dissemination of work


None</gtr:impact><gtr:outcomeId>545cc3005cefb2.47821930</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TAILoR: Lessons from a multi-arm multi-stage clinical trial in HIV/AIDS (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6DBD2F0F-5760-45A4-9746-EFD59477CBAB</gtr:id><gtr:impact>Dissemination of work</gtr:impact><gtr:outcomeId>58ac1f723f0196.80317864</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, NWCTC meeting, Manchester (PB)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A31E4AE5-F015-4009-90A9-DAD9D084B55A</gtr:id><gtr:impact>Discussion

Potential recruits for the START project</gtr:impact><gtr:outcomeId>54574019b75e43.32686546</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Workshop Approaches to deferred consent in the EcLiPSE trial February 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>37511845-BC72-43CA-95FA-7B4EFB922928</gtr:id><gtr:impact>Training on how recruitment and consent should be sought in the EcLiPSE trial, which included a video and evidence based recommendation on how deferred consent should be sought.

Before the session clinicians voiced concerns about recruitment to the trial due to the use of deferred consent. After the session clinicians were more supportive of the approach to recruitment and consent. The training video was described as a useful tool.</gtr:impact><gtr:outcomeId>568e2360e1e5c0.29082357</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Florence 2014 (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4AAB2726-10D5-4392-BB58-20C83A1F2FD2</gtr:id><gtr:impact>Wider dissemination of work

None at present</gtr:impact><gtr:outcomeId>54576eb6da98b2.80876374</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Joint meeting of Danish and Swedish societies for biopharmaceutical/medical statistics 2014 (LH)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8E71DBF2-62A2-4F27-98F6-8974BC1F6545</gtr:id><gtr:impact>Wider dissemination of work


None</gtr:impact><gtr:outcomeId>545cc3fd5bd500.48718394</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Germany 2014 (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>82EB2F4C-2E1A-4B80-B6A4-2F00F98C11C7</gtr:id><gtr:impact>Wider dissemination of work

None at present</gtr:impact><gtr:outcomeId>54576e0b938c85.44027469</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>A qualitative feasibility study to inform fluids in shock (fish) - a pilot randomised controlled trial of fluid bolus therapy in septic shock. 30th Paediatric Intensive Care society Annual Scientific Meeting  (KW)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A362200D-2988-431E-9F41-48FA80918707</gtr:id><gtr:impact>To raise awareness and facilitate engagement in the FiSh trial by presenting phase one qualitative findings, which involved members of the public in trial design. This won a prize for best conference presentation and led to discussions with a target journal chief editor- paper now submitted.</gtr:impact><gtr:outcomeId>58ad734a5d0fe2.47415715</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Scottish Primary Care Network meeting 2015 (PB)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>95EE4A65-A49B-48C6-B503-2890933E1F61</gtr:id><gtr:impact>Raising profile of NWHTMR</gtr:impact><gtr:outcomeId>567a625915b2a3.72792895</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>138381</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Commission H2020</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>CORBEL 65428</gtr:fundingRef><gtr:id>65445784-57F6-4473-A6CF-B9B90A8B68D5</gtr:id><gtr:outcomeId>56de8f2aa4fdc2.35769511</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>26143</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Network of Hubs for Trials Methodology Research N62</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>N62</gtr:fundingRef><gtr:id>E2B17FEB-C584-4866-ADEE-C04E743303E7</gtr:id><gtr:outcomeId>567a5e9e3455b0.65964895</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9817</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC HTMR Network Project Funding</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>N83</gtr:fundingRef><gtr:id>3939DEDE-DE17-4838-B076-6A480B8F3B16</gtr:id><gtr:outcomeId>58a5c48549f392.11701042</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>136000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research B1</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>B1</gtr:fundingRef><gtr:id>7DF46AF9-6D13-4FAC-B76F-B4004CCF6F43</gtr:id><gtr:outcomeId>545368e4a4e834.93584545</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7051</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC HTMR Network Project Funding</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>N76</gtr:fundingRef><gtr:id>94818A87-41E4-4B65-B4FD-BE28D41CF37B</gtr:id><gtr:outcomeId>58a5c3caaa8ce5.68063297</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Methodology Research Panel</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>64A5AD33-E778-43E0-810A-893F5DEF7A9F</gtr:id><gtr:outcomeId>56c34269f04416.87294325</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>14950</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Network of Hubs for Trials Methodology Research N55</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>N55</gtr:fundingRef><gtr:id>D90130D9-6A3D-4759-8A0B-05B0EE388B54</gtr:id><gtr:outcomeId>56c33f4e570ab2.74780916</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>345000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC MRP</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M005755/1</gtr:fundingRef><gtr:id>CEF6845E-AA61-49A4-BA86-B42A595BAC99</gtr:id><gtr:outcomeId>567a5f158d4210.90121782</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1536010</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR HTA</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>12/127</gtr:fundingRef><gtr:id>91D405E2-7028-474D-9BAC-3BC2848A7B62</gtr:id><gtr:outcomeId>545b5369964dc7.98416589</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>475140</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>NIHR HTA</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>13/04/105</gtr:fundingRef><gtr:id>6108CB57-4A8C-4647-B344-DA8831459753</gtr:id><gtr:outcomeId>567a5e17589f47.04611837</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1778335</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR EME</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>F3A64871-E4DD-477C-922A-DC2C6B0B3EB2</gtr:id><gtr:outcomeId>56c342c210a8e2.83728300</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>171229</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K024310/1</gtr:fundingRef><gtr:id>D384B94C-C9BA-4E9B-B42E-1B8A970A22FF</gtr:id><gtr:outcomeId>5453679c4d3278.24562048</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2500000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Initial Training Networks (ITN)</gtr:department><gtr:description>EU Marie Curie ITN</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:fundingRef>633567</gtr:fundingRef><gtr:id>C101C479-652C-4DD1-8D42-8CCADFE33610</gtr:id><gtr:outcomeId>567a5fe7664064.04191596</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>229405</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Research for Patient Benefit</gtr:department><gtr:description>Renehan A and Williamson PR (Joint PIs). Core outcome set for anal cancer studies</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>PB-PG-1013-32064</gtr:fundingRef><gtr:id>CCD47D9B-C21A-4CAB-9E9A-4BB8E6AF26B0</gtr:id><gtr:outcomeId>58ad99c61523c8.43353091</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>327080</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Methodology Research Panel</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1E32CE30-0509-41AA-909B-6D0DDB861CC5</gtr:id><gtr:outcomeId>56c341719bd688.43184312</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>41523</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Network of Hubs for Trials Methodology Research KW</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D195F169-7C64-4297-B310-053D23016748</gtr:id><gtr:outcomeId>567a5d8c647913.63275933</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1370000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR HTA</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>12/173/74</gtr:fundingRef><gtr:id>FBD1C839-D51B-4D61-B1FC-8C1B963C8516</gtr:id><gtr:outcomeId>545b53c5ccaa23.57431842</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>42251</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>School for Primary Care Research Capacity</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>FB87A752-EDCC-4486-A53B-3F27D5637121</gtr:id><gtr:outcomeId>54574509952489.89839085</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>34267</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC HTMR Network Project Funding</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>N78</gtr:fundingRef><gtr:id>730410C2-259B-4672-A562-17CF707B3079</gtr:id><gtr:outcomeId>58a5c42eeac965.68232766</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90261</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research B2</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>B2</gtr:fundingRef><gtr:id>8017B701-FAAC-4254-9DF3-85DC4A6317CB</gtr:id><gtr:outcomeId>545cc655c5df64.43559615</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6472</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research R36</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>R36</gtr:fundingRef><gtr:id>0950A331-7C96-4B5E-B693-6D0C660144C9</gtr:id><gtr:outcomeId>545366a2b312d9.54880428</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35196</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC HTMR Network Project Funding</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>N89</gtr:fundingRef><gtr:id>9C2DBE1B-BDF1-4F2C-B497-ECA1BE904FDF</gtr:id><gtr:outcomeId>58a5c4fe6f45c4.85160455</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3864090</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Innovative Training Network: MIROR (Methods in Research on Research)</gtr:description><gtr:end>2020-02-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>H2020-MSCA-ITN-2015</gtr:fundingRef><gtr:id>FACF6839-C9A1-4E2F-8880-6031C23DC37C</gtr:id><gtr:outcomeId>58aea86654eb68.63332130</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>345000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M005755/1</gtr:fundingRef><gtr:id>E696942B-0ECF-4619-9B81-AEDE692457A9</gtr:id><gtr:outcomeId>54536934104971.12166318</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3100000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>European Commission</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>633567</gtr:fundingRef><gtr:id>51B7097A-371A-420E-B7E3-3A8184C6BE70</gtr:id><gtr:outcomeId>54536a02686137.07822049</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>94500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR RMF</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>94B9519D-8E3D-415E-AA37-1434E40E593F</gtr:id><gtr:outcomeId>56c342226a83f3.95912668</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research R46</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>R46</gtr:fundingRef><gtr:id>DBEB5D65-4EC9-4A0A-B485-EB5C45B97019</gtr:id><gtr:outcomeId>5457442c108ca8.87051753</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>23186</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC HTMR Network Project Funding</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>B1(2)</gtr:fundingRef><gtr:id>98BA4D23-7D55-4907-986C-80E1031C4B99</gtr:id><gtr:outcomeId>58a5c53bb9a345.30154597</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>630000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Fellowship Programme</gtr:department><gtr:description>NIHR SRF</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>34DEF634-4A96-48F9-8579-96C4022EC675</gtr:id><gtr:outcomeId>567a607a493bf9.88928831</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>16436</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC HTMR Network Project Funding</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>N84</gtr:fundingRef><gtr:id>28928C55-C770-4C12-9287-B5F3792A593D</gtr:id><gtr:outcomeId>58a5c4c387f429.80066030</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>510575</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>European Commission</gtr:description><gtr:end>2020-04-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>4ECF5A0C-42B0-43D1-9341-29122BA77E3F</gtr:id><gtr:outcomeId>56de91113b9bf8.77477086</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>42004</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Methodology Research Panel</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>340B699E-A641-4D75-B05B-DC1901A7591D</gtr:id><gtr:outcomeId>56c34093552583.51386417</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>395000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L010658/1</gtr:fundingRef><gtr:id>084735DD-06EF-46EA-9D5E-2B4EBCBD6C34</gtr:id><gtr:outcomeId>54536871f32e04.86080830</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250433</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Fellowship Programme</gtr:department><gtr:description>NIHR Post-Doctoral Fellowship</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>PDF-2015-08-044</gtr:fundingRef><gtr:id>AFC5C1AD-2590-4C02-B12B-2C16A71D4031</gtr:id><gtr:outcomeId>56c3411ac19834.25644926</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>23393</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research R39</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>R39</gtr:fundingRef><gtr:id>E6129271-07A8-4C35-A552-629A34246AF7</gtr:id><gtr:outcomeId>545365aa00d361.60463151</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7461</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Network of Hubs for Trials Methodology Research N67</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>N67</gtr:fundingRef><gtr:id>A211D49C-1449-42AA-83D0-1C1A8A0DF1C1</gtr:id><gtr:outcomeId>56c33fc7532b61.84891119</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>12431</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Network of Hubs for Trials Methodology Research N68</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>N68</gtr:fundingRef><gtr:id>E4897EAB-688B-4BCB-9D5D-231822BB15A5</gtr:id><gtr:outcomeId>56c34014c85ee3.48553144</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>DelphiManager is a web based system designed to facilitate the building and management of Delphi surveys.</gtr:description><gtr:id>AD81A0EA-3AA3-4724-9063-48B0CEB92904</gtr:id><gtr:impact>Since its development the software has been or is currently being used in 18 studies.</gtr:impact><gtr:outcomeId>56d59c3ecf2162.06567972</gtr:outcomeId><gtr:title>Delphi Manager</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://cometinitiative.org/DelphiManager/</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>276647C9-64D2-44E6-B1ED-92C1BE7309EC</gtr:id><gtr:title>TO THE EDITOR.</gtr:title><gtr:parentPublicationTitle>Spine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50f59c90b3ae1bcfadec9d1acedc8211"><gtr:id>50f59c90b3ae1bcfadec9d1acedc8211</gtr:id><gtr:otherNames>Kolias AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0362-2436</gtr:issn><gtr:outcomeId>58a316aa844b32.88751940</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84272353-741F-49C5-8DC9-9F6B1EA658DE</gtr:id><gtr:title>Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size.</gtr:title><gtr:parentPublicationTitle>Journal of personalized medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dba5f41529e691a0b897299211947344"><gtr:id>dba5f41529e691a0b897299211947344</gtr:id><gtr:otherNames>Antoniou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2075-4426</gtr:issn><gtr:outcomeId>5a969475b08406.13291054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A4A69DB-7414-453B-B527-761D181AF4E8</gtr:id><gtr:title>Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dad1f1be8d8a2beade14483300459fec"><gtr:id>dad1f1be8d8a2beade14483300459fec</gtr:id><gtr:otherNames>McCann LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56d9a200ae28a0.47398466</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6378EB28-AE9D-4DAD-A7FF-781632F7F5ED</gtr:id><gtr:title>Flexible sequential designs for multi-arm clinical trials.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/510d6ad383626fd3437a711786695ba0"><gtr:id>510d6ad383626fd3437a711786695ba0</gtr:id><gtr:otherNames>Magirr D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>54576bed5e44f5.48152903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BF4EDCF-5372-48D7-8A26-7356D8B873F8</gtr:id><gtr:title>The management of Otitis Media with Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19119d6bec94a5ce103a164d876a00bf"><gtr:id>19119d6bec94a5ce103a164d876a00bf</gtr:id><gtr:otherNames>Bruce I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn><gtr:outcomeId>58a313d100cf59.22041001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEE603E7-A847-4B5E-BA47-4D587CC4F19F</gtr:id><gtr:title>How should individual participant data (IPD) from publicly funded clinical trials be shared?</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e74e8623ca55eface3c41e51bceb20"><gtr:id>63e74e8623ca55eface3c41e51bceb20</gtr:id><gtr:otherNames>Tudur Smith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>56b0c90dac1e66.96174192</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8BA77E5-DE01-4B1F-9D98-36E830C75C6E</gtr:id><gtr:title>Interventions in randomised controlled trials in surgery: issues to consider during trial design.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/358b24fc3fa6ab7e39ee3c04a3952913"><gtr:id>358b24fc3fa6ab7e39ee3c04a3952913</gtr:id><gtr:otherNames>Blencowe NS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58a313d124fc49.36005647</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>647EE5F2-EE5D-4C56-9E0B-26AC95A09172</gtr:id><gtr:title>A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a17f519190d217d4e666d854dbdf4787"><gtr:id>a17f519190d217d4e666d854dbdf4787</gtr:id><gtr:otherNames>Kirkham JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>5989bb93d3d9a9.35584921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AC7B378-88FF-4AB6-9543-992E0806078B</gtr:id><gtr:title>Core outcome research measures in anal cancer (CORMAC): protocol for systematic review, qualitative interviews and Delphi survey to develop a core outcome set in anal cancer.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9035611da25498ae77452adf0207b6ce"><gtr:id>9035611da25498ae77452adf0207b6ce</gtr:id><gtr:otherNames>Fish R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5a969a37077d62.11026208</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FECDA054-2E05-40BC-82AB-6B091840893E</gtr:id><gtr:title>Core Health Outcomes In Childhood Epilepsy (CHOICE): protocol for the selection of a core outcome set.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/879042325d3c977391eb4e1505b7fdd6"><gtr:id>879042325d3c977391eb4e1505b7fdd6</gtr:id><gtr:otherNames>Morris C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5a9696f1c97636.35643611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE2E40D9-6AF9-4335-8486-FBC9789648D7</gtr:id><gtr:title>Patient and public involvement in the early stages of clinical trial development: a systematic cohort investigation.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d21017d656b537490aad9baf03f046fc"><gtr:id>d21017d656b537490aad9baf03f046fc</gtr:id><gtr:otherNames>Gamble C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>545355f12676a6.80849085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9353D5E-3258-478A-8FF0-754C2FDF2C2E</gtr:id><gtr:title>Guidelines for the Content of Statistical Analysis Plans in Clinical Trials.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d21017d656b537490aad9baf03f046fc"><gtr:id>d21017d656b537490aad9baf03f046fc</gtr:id><gtr:otherNames>Gamble C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>5a8eb1a180f678.09823758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4493867D-9F15-42D8-BB57-CE38C5F2DEF5</gtr:id><gtr:title>Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the EcLiPSE study: study protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a4777fabf9e60a1f0ed2c385006dc65"><gtr:id>6a4777fabf9e60a1f0ed2c385006dc65</gtr:id><gtr:otherNames>Lyttle MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>59b143e4b58f12.16040512</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>533265DE-CC2C-4F2D-BA7A-3B7CC0DEA26F</gtr:id><gtr:title>How individual participant data meta-analyses have influenced trial design, conduct, and analysis.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/663c60b99db378e47bc2ef1efd6bb108"><gtr:id>663c60b99db378e47bc2ef1efd6bb108</gtr:id><gtr:otherNames>Tierney JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>56b0c90e4bfb89.88687671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40E948D9-DF5A-47C5-A406-A7D8394734C3</gtr:id><gtr:title>UK publicly funded Clinical Trials Units supported a controlled access approach to share individual participant data but highlighted concerns.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50c53ac5efc52c6e7ca263d0bf9ed86a"><gtr:id>50c53ac5efc52c6e7ca263d0bf9ed86a</gtr:id><gtr:otherNames>Hopkins C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>56b0c90e14f515.79078336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>195CB6CD-3845-4B2A-BAC5-459F155E4D9E</gtr:id><gtr:title>A cohort examination to establish reporting of the remit and function of Trial Steering Committees in randomised controlled trials.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a328dde90a8c07550067687ea668cc31"><gtr:id>a328dde90a8c07550067687ea668cc31</gtr:id><gtr:otherNames>Conroy EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5a969a36c0a772.15036319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AD7470D-85AD-44A1-A984-64445F3F9A42</gtr:id><gtr:title>Development of a core outcome set for research and audit studies in reconstructive breast surgery.</gtr:title><gtr:parentPublicationTitle>The British journal of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/217edbad5ea0e4d19bb1e17ecd503e55"><gtr:id>217edbad5ea0e4d19bb1e17ecd503e55</gtr:id><gtr:otherNames>Potter S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1323</gtr:issn><gtr:outcomeId>5675e89c754c9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6429687-7D7D-4A05-A377-B507B16FE1C1</gtr:id><gtr:title>Deferred Consent for Randomized Controlled Trials in Emergency Care Settings.</gtr:title><gtr:parentPublicationTitle>Pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f80192119d5ee3ba51bad3c6e4af25"><gtr:id>66f80192119d5ee3ba51bad3c6e4af25</gtr:id><gtr:otherNames>Harron K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0031-4005</gtr:issn><gtr:outcomeId>5672d2c25c49e9.78231104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E88E494B-2853-4008-9D51-1CC0F60F9509</gtr:id><gtr:title>Bayesian adaptive dose-escalation procedures for binary and continuous responses utilizing a gain function.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76a3e483d2d8757fca6e7fafe6658f4e"><gtr:id>76a3e483d2d8757fca6e7fafe6658f4e</gtr:id><gtr:otherNames>Yeung WY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>5672d3c0137e90.62919695</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A25B3D4A-E85F-4DAA-8546-E05BCE715A1E</gtr:id><gtr:title>Sharing and reuse of individual participant data from clinical trials: principles and recommendations.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9736d456ea3d4a1defb3aa230c1ef0d1"><gtr:id>9736d456ea3d4a1defb3aa230c1ef0d1</gtr:id><gtr:otherNames>Ohmann C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5a969ca32fa249.77579088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B05B053-B301-4E99-A556-B5AEEA5913F1</gtr:id><gtr:title>One-stage and two-stage designs for phase II clinical trials with survival endpoints.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd07d27aa98f25db14362e53335a0653"><gtr:id>dd07d27aa98f25db14362e53335a0653</gtr:id><gtr:otherNames>Whitehead J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>545353d4790421.61796739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>343D49C6-159E-47E1-85A0-7202AAF4FC68</gtr:id><gtr:title>Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb7179ac7d2e5af84b1f2d60f510a332"><gtr:id>fb7179ac7d2e5af84b1f2d60f510a332</gtr:id><gtr:otherNames>Hill-McManus D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>59b79c5a9fb3a8.06496981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1C55575-D552-4808-8F5B-5520AF4AE360</gtr:id><gtr:title>Core outcome research measures in anal cancer.</gtr:title><gtr:parentPublicationTitle>Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9035611da25498ae77452adf0207b6ce"><gtr:id>9035611da25498ae77452adf0207b6ce</gtr:id><gtr:otherNames>Fish R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1462-8910</gtr:issn><gtr:outcomeId>5a969b65a83c26.72217474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8122C84-0285-4DD7-986E-EFEDDCF415EC</gtr:id><gtr:title>What Difference Does Patient and Public Involvement Make and What Are Its Pathways to Impact? Qualitative Study of Patients and Researchers from a Cohort of Randomised Clinical Trials.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/168e81ae69da69d2e032a2401677a564"><gtr:id>168e81ae69da69d2e032a2401677a564</gtr:id><gtr:otherNames>Dudley L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5672cfa298f147.08166785</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CB4F6A3-1318-49BF-BE4D-94A1FBBA2969</gtr:id><gtr:title>Communication with young people in paediatric and adult endocrine consultations: an intervention development and feasibility study.</gtr:title><gtr:parentPublicationTitle>BMC endocrine disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c05bb2a5b26b6c77adba971f4f06176"><gtr:id>1c05bb2a5b26b6c77adba971f4f06176</gtr:id><gtr:otherNames>Downing J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1472-6823</gtr:issn><gtr:outcomeId>59b143e5397a92.57036495</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FFB91DA-7A76-4891-A633-841115C39A87</gtr:id><gtr:title>Rare disease prevention and treatment: the need for a level playing field.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f3b59c01318db7c233a9f9e667e937a"><gtr:id>4f3b59c01318db7c233a9f9e667e937a</gtr:id><gtr:otherNames>Hughes DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>5a9696f205fa99.10012000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C676089D-5B9F-4909-9A6B-C26857C9D252</gtr:id><gtr:title>RE: Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72c643c9b276aeb624dc27d5321403bd"><gtr:id>72c643c9b276aeb624dc27d5321403bd</gtr:id><gtr:otherNames>Main BG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>56d9a33dca9565.41613753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B2B4B27-036F-40EC-B388-C3129091B0C6</gtr:id><gtr:title>Sharing individual participant data from clinical trials: an opinion survey regarding the establishment of a central repository.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e74e8623ca55eface3c41e51bceb20"><gtr:id>63e74e8623ca55eface3c41e51bceb20</gtr:id><gtr:otherNames>Tudur Smith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_540e15fe15f2604d7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>825C44C3-8CA6-4E9B-8AB4-73E0FCCBEDE4</gtr:id><gtr:title>Overcoming barriers to recruiting ethnic minorities to mental health research: a typology of recruitment strategies.</gtr:title><gtr:parentPublicationTitle>BMC psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ffcc46ab200ea5403ce7b5d0fea63c0"><gtr:id>9ffcc46ab200ea5403ce7b5d0fea63c0</gtr:id><gtr:otherNames>Waheed W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-244X</gtr:issn><gtr:outcomeId>5672d309bcd6b5.58604902</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E369601-CF0D-4B48-9D5B-F86D05E22FF4</gtr:id><gtr:title>A qualitative feasibility study to inform a randomised controlled trial of fluid bolus therapy in septic shock.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1aafe7720430b2d5be218d8b04363bf"><gtr:id>a1aafe7720430b2d5be218d8b04363bf</gtr:id><gtr:otherNames>O'Hara CB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>59b143e415af07.51922473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D21D474-CCBF-4913-89CA-AC6046AFFA3C</gtr:id><gtr:title>Resource implications of preparing individual participant data from a clinical trial to share with external researchers.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e74e8623ca55eface3c41e51bceb20"><gtr:id>63e74e8623ca55eface3c41e51bceb20</gtr:id><gtr:otherNames>Tudur Smith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>59956fcdba9b81.14281297</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA416C55-1641-494C-A01E-CFFA58E5954C</gtr:id><gtr:title>Interventions to improve recruitment and retention in clinical trials: a survey and workshop to assess current practice and future priorities.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ded55b189099956a0ac27e9da424f376"><gtr:id>ded55b189099956a0ac27e9da424f376</gtr:id><gtr:otherNames>Bower P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>545355f15077e2.30803484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFDD87B8-CACA-4AB3-81AC-E94A60E4E1D2</gtr:id><gtr:title>Economics of Pharmacogenetic-Guided Treatments: Underwhelming or Overstated?</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f3b59c01318db7c233a9f9e667e937a"><gtr:id>4f3b59c01318db7c233a9f9e667e937a</gtr:id><gtr:otherNames>Hughes DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>5a9696f2554cc1.97136917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55B86ECF-CB9D-43EB-911C-C290EBBF02D4</gtr:id><gtr:title>Development of a core outcome set to determine the overall treatment success of acute uncomplicated appendicitis in children: a study protocol</gtr:title><gtr:parentPublicationTitle>BMJ Paediatrics Open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2f48740d0484e74d70d8cb961706fba"><gtr:id>a2f48740d0484e74d70d8cb961706fba</gtr:id><gtr:otherNames>Sherratt F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>59b144b7e47c24.73450975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E70100D2-07B9-469F-8B6D-D483E8C58ECA</gtr:id><gtr:title>Bridging the gap: a review of dose investigations in paediatric investigation plans.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f1f2122640ae0c1eeb2718fb1cb8899"><gtr:id>6f1f2122640ae0c1eeb2718fb1cb8899</gtr:id><gtr:otherNames>Hampson LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>545353d450a8f8.64180943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7F231F0-B6AA-4AC3-8FDF-4DC334CED09F</gtr:id><gtr:title>COS-STAR: a reporting guideline for studies developing core outcome sets (protocol).</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a17f519190d217d4e666d854dbdf4787"><gtr:id>a17f519190d217d4e666d854dbdf4787</gtr:id><gtr:otherNames>Kirkham JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>568e27c72e6a65.30121969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6B24583-EFB7-4079-B840-240BC5D34964</gtr:id><gtr:title>Dialogue on Developing Consensus on Measurement and Presentation of Patient-important Outcomes, Using Pain Outcomes as an Exemplar, in Systematic Reviews: A Preconference Meeting at OMERACT 12.</gtr:title><gtr:parentPublicationTitle>The Journal of rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e575337c2f96bce9875615270ad88d0"><gtr:id>6e575337c2f96bce9875615270ad88d0</gtr:id><gtr:otherNames>Tugwell PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0315-162X</gtr:issn><gtr:outcomeId>56d9a201b53d16.98886138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B816A7E-04AB-4D81-9FB2-FEFDB307E9DE</gtr:id><gtr:title>Core Outcomes in Ventilation Trials (COVenT): protocol for a core outcome set using a Delphi survey with a nested randomised trial and observational cohort study.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/119a0874da92103ba21bef832c59b55c"><gtr:id>119a0874da92103ba21bef832c59b55c</gtr:id><gtr:otherNames>Blackwood B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56d9a1a4758616.84066481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CFC62A7-A15A-44C2-9CBA-2647E71059C8</gtr:id><gtr:title>Training health professionals to recruit into challenging randomized controlled trials improved confidence: the development of the QuinteT RCT Recruitment Training Intervention.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/131290eb61bf5bf74038ca79e8512782"><gtr:id>131290eb61bf5bf74038ca79e8512782</gtr:id><gtr:otherNames>Mills N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>5a8da7552c6950.96286541</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A64E42B-1675-4FAA-8019-3ECA1631DB97</gtr:id><gtr:title>Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>5672d402377be1.51474804</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC65DBFD-AF1F-49C1-A8E6-42E9CB99E059</gtr:id><gtr:title>Questioning assent: how are children's views included as families make decisions about clinical trials?</gtr:title><gtr:parentPublicationTitle>Child: care, health and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fbbea275d6bcc01f7beee52fd041848"><gtr:id>0fbbea275d6bcc01f7beee52fd041848</gtr:id><gtr:otherNames>Madden L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-1862</gtr:issn><gtr:outcomeId>58a42fd0501ba7.45557597</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01F7E113-8219-4317-8156-36477A017AFE</gtr:id><gtr:title>Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03db2458b85a51d20f3a242bb7b7fd4b"><gtr:id>03db2458b85a51d20f3a242bb7b7fd4b</gtr:id><gtr:otherNames>Hughes D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>585d5427cb68b7.97536564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E847ACAE-B595-4D4B-9E9A-36760952AFE3</gtr:id><gtr:title>Citation analysis did not provide a reliable assessment of core outcome set uptake.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68063dba9e43437ad661605c12432181"><gtr:id>68063dba9e43437ad661605c12432181</gtr:id><gtr:otherNames>Barnes KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>5989bb61c09de8.88032810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C010DA23-B930-47E9-8096-AEDD6E2E9C05</gtr:id><gtr:title>The Importance of Integration of Stakeholder Views in Core Outcome Set Development: Otitis Media with Effusion in Children with Cleft Palate.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/563710b15a31a4a26184221dac7791dd"><gtr:id>563710b15a31a4a26184221dac7791dd</gtr:id><gtr:otherNames>Harman NL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675e76a83cd2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33E172FB-A508-468B-9796-0739589F13EB</gtr:id><gtr:title>Bayesian methods for the design and interpretation of clinical trials in very rare diseases.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f1f2122640ae0c1eeb2718fb1cb8899"><gtr:id>6f1f2122640ae0c1eeb2718fb1cb8899</gtr:id><gtr:otherNames>Hampson LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>545cc0deef80d5.79366423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2986A779-36BF-4B2D-95AF-FE482F83D120</gtr:id><gtr:title>Risk-proportionate clinical trial monitoring: an example approach from a non-commercial trials unit.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e74e8623ca55eface3c41e51bceb20"><gtr:id>63e74e8623ca55eface3c41e51bceb20</gtr:id><gtr:otherNames>Tudur Smith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_540e15fe15f1ab11b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D13C27A-0F5E-4B4E-83AE-AEFF55983B56</gtr:id><gtr:title>Informing efficient randomised controlled trials: exploration of challenges in developing progression criteria for internal pilot studies.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6991770736449cc3190b4c13d1e92c2"><gtr:id>f6991770736449cc3190b4c13d1e92c2</gtr:id><gtr:otherNames>Avery KN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>58ac124b3c39c1.40725776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4812E207-E78A-4346-81B9-D11356D1A361</gtr:id><gtr:title>A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/001663d69b738304faf38b5a13e5c02c"><gtr:id>001663d69b738304faf38b5a13e5c02c</gtr:id><gtr:otherNames>Dodd S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>5a82bbdd480129.30397494</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E32EB5B0-04F4-4106-B7DE-BC9823282C7B</gtr:id><gtr:title>A patient and public involvement (PPI) toolkit for meaningful and flexible involvement in clinical trials - a work in progress.</gtr:title><gtr:parentPublicationTitle>Research involvement and engagement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5faa4b52fd7584d7b4855ee298032519"><gtr:id>5faa4b52fd7584d7b4855ee298032519</gtr:id><gtr:otherNames>Bagley HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2056-7529</gtr:issn><gtr:outcomeId>58aab3c8c1f918.08987719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>400077DB-6064-4F11-AEF7-E40E906C0A79</gtr:id><gtr:title>A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration.</gtr:title><gtr:parentPublicationTitle>The patient</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cbbf8edefdbc89ec594d06a4a1c7208"><gtr:id>5cbbf8edefdbc89ec594d06a4a1c7208</gtr:id><gtr:otherNames>Ridyard CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1178-1653</gtr:issn><gtr:outcomeId>585d678872acc2.51329034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CEE1537-7E8F-4DC9-B0C6-C315CB28A54B</gtr:id><gtr:title>A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia.</gtr:title><gtr:parentPublicationTitle>Pregnancy hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/378740d1e59945b4482b19e9cd8a6e66"><gtr:id>378740d1e59945b4482b19e9cd8a6e66</gtr:id><gtr:otherNames>Duffy JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2210-7789</gtr:issn><gtr:outcomeId>58a313d0cddb32.64974915</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9FE41A6-BFB1-4FC1-A19E-66D3999937D2</gtr:id><gtr:title>Core outcome sets and trial registries.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f10f6b8faa715faa1a1670e0712441c4"><gtr:id>f10f6b8faa715faa1a1670e0712441c4</gtr:id><gtr:otherNames>Clarke M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5675e468a22a9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>669FFDE7-3D4B-4EB0-AA52-B03BA6F00A15</gtr:id><gtr:title>The natural history of conducting and reporting clinical trials: interviews with trialists.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bd7807b7e314ccca158a271ae22f156"><gtr:id>6bd7807b7e314ccca158a271ae22f156</gtr:id><gtr:otherNames>Smyth RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>doi_55f983983b1a4589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECE9C773-810D-4C41-8F6C-D43ACD43DD4D</gtr:id><gtr:title>A framework for the design, conduct and interpretation of randomised controlled trials in the presence of treatment changes.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/001663d69b738304faf38b5a13e5c02c"><gtr:id>001663d69b738304faf38b5a13e5c02c</gtr:id><gtr:otherNames>Dodd S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5a2fd6984993e0.69837687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CB6ADD0-C098-4455-BB22-302C860181C3</gtr:id><gtr:title>Exploring changes over time and characteristics associated with data retrieval across individual participant data meta-analyses: systematic review.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c27ebb6aa8c3da636a6094b1b3dce9e"><gtr:id>0c27ebb6aa8c3da636a6094b1b3dce9e</gtr:id><gtr:otherNames>Nevitt SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>59956c9826eac7.53113531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>599E3886-F9DB-449F-A10B-916F2DF8C4AD</gtr:id><gtr:title>Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f668352004702303f2e8e0e2b26d93"><gtr:id>21f668352004702303f2e8e0e2b26d93</gtr:id><gtr:otherNames>Vale CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>56b0c90eb25534.48692063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88C4A9C4-EA1E-4FE7-8258-E05CA07E5F03</gtr:id><gtr:title>A framework for prospectively defining progression rules for internal pilot studies monitoring recruitment.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f1f2122640ae0c1eeb2718fb1cb8899"><gtr:id>6f1f2122640ae0c1eeb2718fb1cb8899</gtr:id><gtr:otherNames>Hampson LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>599c2571ed87d6.30317444</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CA71E05-ECB2-47AB-B885-B8AF770D3893</gtr:id><gtr:title>Asymmetric inner wedge group sequential tests with applications to verifying whether effective drug concentrations are similar in adults and children.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f1f2122640ae0c1eeb2718fb1cb8899"><gtr:id>6f1f2122640ae0c1eeb2718fb1cb8899</gtr:id><gtr:otherNames>Hampson LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>59b1199adbd076.73078802</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5041E9C-493D-420E-B18C-F05597B50170</gtr:id><gtr:title>The impact of advertising patient and public involvement on trial recruitment: embedded cluster randomised recruitment trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58be82b51de6ede87dc16407a500161e"><gtr:id>58be82b51de6ede87dc16407a500161e</gtr:id><gtr:otherNames>Hughes-Morley A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58a42fd0294d38.01783044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54C7F733-A006-4623-920A-70682A902A13</gtr:id><gtr:title>Outcome reporting across randomised controlled trials evaluating therapeutic interventions for pre-eclampsia.</gtr:title><gtr:parentPublicationTitle>BJOG : an international journal of obstetrics and gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79f0e72d3a46470fa1661962e9f61933"><gtr:id>79f0e72d3a46470fa1661962e9f61933</gtr:id><gtr:otherNames>Duffy J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1470-0328</gtr:issn><gtr:outcomeId>599c25dd432f43.97663520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F31C0AD-4C2D-417F-B1EA-7FA478178EAF</gtr:id><gtr:title>Research with children and young people: not on them.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a612a1ce16a59d5f79af3f9f4e7c57f9"><gtr:id>a612a1ce16a59d5f79af3f9f4e7c57f9</gtr:id><gtr:otherNames>Sammons HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>58a42fd0a7f3b1.11668378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F251BA35-071A-49AB-82B0-DFA1AF89ECF9</gtr:id><gtr:title>Making randomised trials more efficient: report of the first meeting to discuss the Trial Forge platform.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59fac098248b340aabd71315601019f7"><gtr:id>59fac098248b340aabd71315601019f7</gtr:id><gtr:otherNames>Treweek S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56d9a200def1f2.81953454</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>745102AD-C339-4A17-8FD4-3AA0FF119B56</gtr:id><gtr:title>Priorities for methodological research on patient and public involvement in clinical trials: A modified Delphi process.</gtr:title><gtr:parentPublicationTitle>Health expectations : an international journal of public participation in health care and health policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a60ca4562193248cecd9df322b5f60d"><gtr:id>6a60ca4562193248cecd9df322b5f60d</gtr:id><gtr:otherNames>Kearney A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1369-6513</gtr:issn><gtr:outcomeId>59b143e48a3254.98322331</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55ACC657-D7B5-4369-9D42-EDAE3693E8CF</gtr:id><gtr:title>Core outcome sets for use in effectiveness trials involving people with bipolar and schizophrenia in a community-based setting (PARTNERS2): study protocol for the development of two core outcome sets.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26a02c8ac740b6e5834f02387a5ba7b0"><gtr:id>26a02c8ac740b6e5834f02387a5ba7b0</gtr:id><gtr:otherNames>Keeley T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56d9a201421d44.46365678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>209C935C-BEC6-485B-A3DF-FF6364097B4F</gtr:id><gtr:title>Adjustment for treatment changes in epilepsy trials: A comparison of causal methods for time-to-event outcomes.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/001663d69b738304faf38b5a13e5c02c"><gtr:id>001663d69b738304faf38b5a13e5c02c</gtr:id><gtr:otherNames>Dodd S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>5a9693e4b33b31.59593816</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3729CB82-B400-45A1-903F-619A5E67FBA5</gtr:id><gtr:title>A little more conversation please? Qualitative study of researchers' and patients' interview accounts of training for patient and public involvement in clinical trials.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/168e81ae69da69d2e032a2401677a564"><gtr:id>168e81ae69da69d2e032a2401677a564</gtr:id><gtr:otherNames>Dudley L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>565db6f3c6cee0.00694911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEAC5320-2577-4052-8A0E-6FD493B51FB8</gtr:id><gtr:title>A practical design for a dual-agent dose-escalation trial that incorporates pharmacokinetic data.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/929c01fad63b4752722556c629106f10"><gtr:id>929c01fad63b4752722556c629106f10</gtr:id><gtr:otherNames>Cotterill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>5672d11f1621b4.75656586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99843B78-97BE-4A84-AEE0-598B9F1F92D6</gtr:id><gtr:title>A Bayesian adaptive design for clinical trials in rare diseases.</gtr:title><gtr:parentPublicationTitle>Computational statistics &amp; data analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/254b5b3b1bdda3ed8097593ccd4f9e51"><gtr:id>254b5b3b1bdda3ed8097593ccd4f9e51</gtr:id><gtr:otherNames>Williamson SF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0167-9473</gtr:issn><gtr:outcomeId>59b11894616244.51348311</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>035BDA82-87AD-45C1-9170-359D23F9EE9B</gtr:id><gtr:title>Multi-arm clinical trials with treatment selection: what can be gained and at what price?</gtr:title><gtr:parentPublicationTitle>Clinical Investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>567a5ad383e5b4.98389975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>220BE997-4A35-48A2-AB3B-96AC6BF608A4</gtr:id><gtr:title>The COMET initiative database: progress and activities update (2014).</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9b52bf0399673b0ce1980ebde0bd0c4"><gtr:id>b9b52bf0399673b0ce1980ebde0bd0c4</gtr:id><gtr:otherNames>Gargon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>568e27c6ef5fd3.76263803</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71D9BD93-905A-456E-9DB7-8BB9B27E16F0</gtr:id><gtr:title>Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6535ed7c52ea3cd73477e3e1c512cc91"><gtr:id>6535ed7c52ea3cd73477e3e1c512cc91</gtr:id><gtr:otherNames>Pushpakom SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>567a5c6c2f82f5.61305792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FA0FAE1-6D18-4EC0-88FA-BD171602DFB5</gtr:id><gtr:title>Adrenal responses to a low-dose short synacthen test in children with asthma.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/733c748369e0b187e9271725febc9547"><gtr:id>733c748369e0b187e9271725febc9547</gtr:id><gtr:otherNames>Hawcutt DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>56b0c90f9459d9.72509279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D6F1F9B-88FD-4757-94EE-2C35825F4D0A</gtr:id><gtr:title>Survey of new 2007 and 2011 Cochrane reviews found 37% of prespecified outcomes not reported.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/676e4055612533a789082d1c4fa1a9cc"><gtr:id>676e4055612533a789082d1c4fa1a9cc</gtr:id><gtr:otherNames>Smith V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>58a313d152a8b1.06598233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B62EA4C9-BAE9-4F2F-BD19-7E1B272A0DCD</gtr:id><gtr:title>How Much Participant Outcome Data Is Missing from Sight: Findings from a Cohort of Trials Submitted to a German Research Ethics Committee.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a17f519190d217d4e666d854dbdf4787"><gtr:id>a17f519190d217d4e666d854dbdf4787</gtr:id><gtr:otherNames>Kirkham JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d71945ff276.78691010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E55405BF-9642-4606-B153-E3B0D9A1A64E</gtr:id><gtr:title>Evaluation and validation of social and psychological markers in randomised trials of complex interventions in mental health: a methodological research programme.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8501d462aa563290c64d7b54079eaa92"><gtr:id>8501d462aa563290c64d7b54079eaa92</gtr:id><gtr:otherNames>Dunn G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn><gtr:outcomeId>56b0c90fc933d8.37801071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C5099A0-6961-4C31-AE9F-B700D8EE299D</gtr:id><gtr:title>Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f3b59c01318db7c233a9f9e667e937a"><gtr:id>4f3b59c01318db7c233a9f9e667e937a</gtr:id><gtr:otherNames>Hughes DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58ac1455dc9af3.32526773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B839079-15B8-46DC-94C0-9E7D3292C2C4</gtr:id><gtr:title>Including patients in core outcome set development: issues to consider based on three workshops with around 100 international delegates</gtr:title><gtr:parentPublicationTitle>Research Involvement and Engagement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fb12c3c6dbff80fe282e4751d9310d7"><gtr:id>6fb12c3c6dbff80fe282e4751d9310d7</gtr:id><gtr:otherNames>Young B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58aab3c89de785.10447387</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>528B2951-8A74-4BDB-A340-62BC55CF4BA7</gtr:id><gtr:title>Re: Neil E. Martin, Laura Massey, Caleb Stowell, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. Eur Urol 2015;67:460-7.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef10e2fc0d09f68bd9fed1aa09dc9d09"><gtr:id>ef10e2fc0d09f68bd9fed1aa09dc9d09</gtr:id><gtr:otherNames>MacLennan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>58a313d178e7c7.68229841</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12D8DCBB-60DD-4CC9-B04E-6BB445D0B4B6</gtr:id><gtr:title>What can we learn from trial decliners about improving recruitment? Qualitative study.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58be82b51de6ede87dc16407a500161e"><gtr:id>58be82b51de6ede87dc16407a500161e</gtr:id><gtr:otherNames>Hughes-Morley A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58a42fd07b28f3.40175558</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17A0780D-9F54-447A-95F7-25B0AA38ED22</gtr:id><gtr:title>Methodology of clinical trials for rare diseases.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e74e8623ca55eface3c41e51bceb20"><gtr:id>63e74e8623ca55eface3c41e51bceb20</gtr:id><gtr:otherNames>Tudur Smith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1521-6942</gtr:issn><gtr:outcomeId>pm_540e15fe15f3ad4d0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B4328E7-30FA-41CA-9637-27F5554E4968</gtr:id><gtr:title>Barriers to recruiting ethnic minorities to mental health research: a systematic review.</gtr:title><gtr:parentPublicationTitle>International journal of methods in psychiatric research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26abd53b6933c80866a7eb492ea6efa6"><gtr:id>26abd53b6933c80866a7eb492ea6efa6</gtr:id><gtr:otherNames>Brown G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1049-8931</gtr:issn><gtr:outcomeId>54573ef8a5b475.80661245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D47C616-5AEB-44FD-83AB-A974A741F8F1</gtr:id><gtr:title>Adaptive designs in clinical trials: why use them, and how to run and report them.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b4ce11d600cea298d5911acf3126187"><gtr:id>7b4ce11d600cea298d5911acf3126187</gtr:id><gtr:otherNames>Pallmann P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>5a995f7ab2e457.93529654</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A67E307-6825-4825-9DC2-A3E294C0809A</gtr:id><gtr:title>Collating the knowledge base for core outcome set development: developing and appraising the search strategy for a systematic review.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9b52bf0399673b0ce1980ebde0bd0c4"><gtr:id>b9b52bf0399673b0ce1980ebde0bd0c4</gtr:id><gtr:otherNames>Gargon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>doi_55f98698632a30e7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7033A41D-C08A-4566-9C8F-901C448B9D91</gtr:id><gtr:title>'Recruitment, recruitment, recruitment' - the need for more focus on retention: a qualitative study of five trials.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c92f3c66fa53b6ec7c71818d337ada01"><gtr:id>c92f3c66fa53b6ec7c71818d337ada01</gtr:id><gtr:otherNames>Daykin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5a9696f27aa577.22185494</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F00CA597-7E9D-449A-9CD4-75C0EA2E9291</gtr:id><gtr:title>Affordable orphan drugs: a role for not-for-profit organizations.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7259b333353167e93fe1569c647a559"><gtr:id>f7259b333353167e93fe1569c647a559</gtr:id><gtr:otherNames>Davies EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>58ac1456100c80.68380451</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC8F4326-0985-4634-B7D7-FD90AD2CE069</gtr:id><gtr:title>'We all want to succeed, but we've also got to be realistic about what is happening': an ethnographic study of relationships in trial oversight and their impact.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c92f3c66fa53b6ec7c71818d337ada01"><gtr:id>c92f3c66fa53b6ec7c71818d337ada01</gtr:id><gtr:otherNames>Daykin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5a8da5ebe021b0.77168772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D61C2D28-20C3-4002-B7B5-7903584E9897</gtr:id><gtr:title>Improving core outcome set development: qualitative interviews with developers provided pointers to inform guidance.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9b52bf0399673b0ce1980ebde0bd0c4"><gtr:id>b9b52bf0399673b0ce1980ebde0bd0c4</gtr:id><gtr:otherNames>Gargon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>59956efed22a16.21038062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7BE1AD9-7FB1-4E40-9C8F-8796D2D04F8F</gtr:id><gtr:title>Multiple imputation of multiple multi-item scales when a full imputation model is infeasible.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/251e8f80dc64f3415ad91ed03022c666"><gtr:id>251e8f80dc64f3415ad91ed03022c666</gtr:id><gtr:otherNames>Plumpton CO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn><gtr:outcomeId>585d53c2af7742.82597937</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8ED501A0-AB8A-44DF-B3D8-10EAFA360877</gtr:id><gtr:title>Factorial versus multi-arm multi-stage designs for clinical trials with multiple treatments.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>59b1195bf151b7.05667741</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BF62225-36DB-4E6A-95FC-1705BF4015BC</gtr:id><gtr:title>Patient and public participation in health care: can we do it better?</gtr:title><gtr:parentPublicationTitle>The American journal of bioethics : AJOB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c5670d6555aab222e77b3ce1b03f7b7"><gtr:id>2c5670d6555aab222e77b3ce1b03f7b7</gtr:id><gtr:otherNames>Frith L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1526-5161</gtr:issn><gtr:outcomeId>545355f0f34a58.19500061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88B4F0B1-753F-41A1-9A4A-D6AB46EDF8E3</gtr:id><gtr:title>Feasibility study to examine discrepancy rates in prespecified and reported outcomes in articles submitted to The BMJ.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bc85a8ee3f20882ce38381b76a2814d"><gtr:id>2bc85a8ee3f20882ce38381b76a2814d</gtr:id><gtr:otherNames>Weston J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>599c28f10678d3.89095398</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60D5D8B8-8A1E-42E4-86EA-1DCB57E6A6B1</gtr:id><gtr:title>Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92032a2603eb4aabc998973c797e3802"><gtr:id>92032a2603eb4aabc998973c797e3802</gtr:id><gtr:otherNames>Dwan K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>545355f0a866f4.61377659</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>128C242D-7BD9-4854-9B53-C6B0BE836B7B</gtr:id><gtr:title>A core outcome set for localised prostate cancer effectiveness trials: protocol for a systematic review of the literature and stakeholder involvement through interviews and a Delphi survey.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef10e2fc0d09f68bd9fed1aa09dc9d09"><gtr:id>ef10e2fc0d09f68bd9fed1aa09dc9d09</gtr:id><gtr:otherNames>MacLennan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56d9a201185874.93056129</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F89D454-CDBC-4B76-846B-CCC47F641DA1</gtr:id><gtr:title>Choosing Important Health Outcomes for Comparative Effectiveness Research: An Updated Review and Identification of Gaps.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1b8fe0fa7245c80331b8c3df36c4481"><gtr:id>e1b8fe0fa7245c80331b8c3df36c4481</gtr:id><gtr:otherNames>Gorst SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58a313cfa30e08.66240698</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64048345-E6BC-4A3F-952C-E382565D2EB3</gtr:id><gtr:title>Development of a core outcome set for clinical trials in rosacea: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9d52b30b49b2483ee0c36a9265943d9"><gtr:id>b9d52b30b49b2483ee0c36a9265943d9</gtr:id><gtr:otherNames>Iyengar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58a313d0a554d2.96552733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA5CAADE-460D-4924-8172-2C6C31696A12</gtr:id><gtr:title>Bayesian clinical trial designs: Another option for trauma trials?</gtr:title><gtr:parentPublicationTitle>The journal of trauma and acute care surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c881d498ae909c2599e5bfb6837e1702"><gtr:id>c881d498ae909c2599e5bfb6837e1702</gtr:id><gtr:otherNames>Jansen JO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2163-0755</gtr:issn><gtr:outcomeId>5a8eb1a1b92d09.63582743</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38A3858B-3649-49B0-A029-74DB04DB7611</gtr:id><gtr:title>How to select outcome measurement instruments for outcomes included in a &amp;quot;Core Outcome Set&amp;quot; - a practical guideline.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dda58bb4c6aa8ac0ca07c995792037da"><gtr:id>dda58bb4c6aa8ac0ca07c995792037da</gtr:id><gtr:otherNames>Prinsen CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58a313d0190468.01677914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87A4042F-2C4D-4229-9B77-E7AB6AA3D45A</gtr:id><gtr:title>Choosing important health outcomes for comparative effectiveness research: An updated systematic review and involvement of low and middle income countries.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89beeefebff77b2e8b99ccf990e6b1e1"><gtr:id>89beeefebff77b2e8b99ccf990e6b1e1</gtr:id><gtr:otherNames>Davis K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a9d47f0054480.18888902</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A91DCEAB-8693-43D0-BA48-F95B1395ADBA</gtr:id><gtr:title>Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov.</gtr:title><gtr:parentPublicationTitle>Orphanet journal of rare diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afdb5ae17d92b68db7e677056f56b55d"><gtr:id>afdb5ae17d92b68db7e677056f56b55d</gtr:id><gtr:otherNames>Hee SW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1750-1172</gtr:issn><gtr:outcomeId>5a969ca3655566.25220762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5CF717D-6ADF-4E1B-B564-3A0DBB874950</gtr:id><gtr:title>Individual participant data meta-analyses compared with meta-analyses based on aggregate data.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e74e8623ca55eface3c41e51bceb20"><gtr:id>63e74e8623ca55eface3c41e51bceb20</gtr:id><gtr:otherNames>Tudur Smith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>58a313d05c65a9.20750260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA10D26A-2C26-4D6B-BF37-DDF6DF579DD7</gtr:id><gtr:title>Using routinely recorded data in the UK to assess outcomes in a randomised controlled trial: The Trials of Access.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ba4e44d98cccc92178b068dea5c3b9d"><gtr:id>4ba4e44d98cccc92178b068dea5c3b9d</gtr:id><gtr:otherNames>Powell GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5a969ca2ec3aa0.31929772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6A01B48-2AB9-4F52-8859-B23D9BB4EC2E</gtr:id><gtr:title>Doing challenging research studies in a patient-centred way: a qualitative study to inform a randomised controlled trial in the paediatric emergency care setting.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef216dd99d26d1b38c076799060e74b1"><gtr:id>ef216dd99d26d1b38c076799060e74b1</gtr:id><gtr:otherNames>Woolfall K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>545355f0cf7a30.65143058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7201B0A1-C169-48FB-A427-701DF97F27D2</gtr:id><gtr:title>A Bayesian approach to dose-finding studies for cancer therapies: incorporating later cycles of therapy.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98dad08937c6b1f24bb89a872f114f3f"><gtr:id>98dad08937c6b1f24bb89a872f114f3f</gtr:id><gtr:otherNames>Sinclair K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>545353d49f8ab0.04270934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7876A5B6-BE52-4792-80D6-90EE95147886</gtr:id><gtr:title>A hybrid method to estimate the minimum effective dose for monotone and non-monotone dose-response relationships.</gtr:title><gtr:parentPublicationTitle>Biometrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0116550b3dfcd7c4b2f420753b124c5"><gtr:id>a0116550b3dfcd7c4b2f420753b124c5</gtr:id><gtr:otherNames>Wolfsegger MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-341X</gtr:issn><gtr:outcomeId>545353d425e1b7.79856693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD378511-15F7-405B-8F2C-3D6CD557334C</gtr:id><gtr:title>Simultaneous confidence regions for multivariate bioequivalence.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b4ce11d600cea298d5911acf3126187"><gtr:id>7b4ce11d600cea298d5911acf3126187</gtr:id><gtr:otherNames>Pallmann P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>59b1179d407911.25377212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CBA9C99-D22B-4852-BD09-8CC0707E56E9</gtr:id><gtr:title>Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76a3e483d2d8757fca6e7fafe6658f4e"><gtr:id>76a3e483d2d8757fca6e7fafe6658f4e</gtr:id><gtr:otherNames>Yeung WY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>59b11858a1a7a4.14544467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>973D269C-EB98-484F-BBEB-6983177B650C</gtr:id><gtr:title>COMET V meeting summary</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53555d6d40d640983e004c534ccf0c72"><gtr:id>53555d6d40d640983e004c534ccf0c72</gtr:id><gtr:otherNames>Gorst S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>58a31789f38176.61847026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CFF2858-DB68-498B-B2DD-B685EBA48DA2</gtr:id><gtr:title>Three nested randomized controlled trials of peer-only or multiple stakeholder group feedback within Delphi surveys during core outcome and information set development.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d6f6270ce3d26861e80b83e1ef74f5a"><gtr:id>2d6f6270ce3d26861e80b83e1ef74f5a</gtr:id><gtr:otherNames>Brookes ST</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58ad8c4e997130.44120573</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84BE21FF-6E45-427C-B652-7967CDF1CA62</gtr:id><gtr:title>The COMET Handbook: version 1.0.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e134234ec325e4d0f2a665f60359eb6d"><gtr:id>e134234ec325e4d0f2a665f60359eb6d</gtr:id><gtr:otherNames>Williamson PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5989bad9da0c62.30619159</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D26B87F4-DD6A-4300-92F0-5C8EACF3D77D</gtr:id><gtr:title>Developing and evaluating multimedia information resources to improve engagement of children, adolescents, and their parents with trials (TRECA study): Study protocol for a series of linked randomised controlled trials.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1aee90dc9258912b2c295b7a462281c0"><gtr:id>1aee90dc9258912b2c295b7a462281c0</gtr:id><gtr:otherNames>Martin-Kerry J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>59b143e50ccbb0.60252800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0EDFEE3-790E-422F-B9FC-A7ADF1C2D38A</gtr:id><gtr:title>Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.</gtr:title><gtr:parentPublicationTitle>Journal of personalized medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dba5f41529e691a0b897299211947344"><gtr:id>dba5f41529e691a0b897299211947344</gtr:id><gtr:otherNames>Antoniou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2075-4426</gtr:issn><gtr:outcomeId>58aac26ec83090.61792241</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C45C2CB-0CC2-4FE4-A9CE-F5EBCA7EE769</gtr:id><gtr:title>Circulating Kidney Injury Molecule 1 Predicts Prognosis and Poor Outcome in Patients With Acetaminophen-Induced Liver Injury.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e875e1050196c8d029bc61e171597736"><gtr:id>e875e1050196c8d029bc61e171597736</gtr:id><gtr:otherNames>Antoine DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56b0c90f307455.86590890</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3064B6F6-7CAA-45B0-BE21-A9068C8F8C40</gtr:id><gtr:title>A core outcome set for neonatal abstinence syndrome: study protocol for a systematic review, parent interviews and a Delphi survey.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bda1b0718b8ffe211e3173ccb76f9a73"><gtr:id>bda1b0718b8ffe211e3173ccb76f9a73</gtr:id><gtr:otherNames>Kelly LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58a313d083a352.11295269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E913F2C9-C118-4D6D-A275-A0F5A2370AEE</gtr:id><gtr:title>Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dba5f41529e691a0b897299211947344"><gtr:id>dba5f41529e691a0b897299211947344</gtr:id><gtr:otherNames>Antoniou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a9d3c7699ece8.34837699</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AC0FED0-84A9-4EBC-B00A-365C82FD8B26</gtr:id><gtr:title>ESPACOMP Medication Adherence Reporting Guidelines (EMERGE): a reactive-Delphi study protocol.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667d739a6775f1e3fab2b94d1229ef5d"><gtr:id>667d739a6775f1e3fab2b94d1229ef5d</gtr:id><gtr:otherNames>Helmy R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>58ac1455b2b120.06659849</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C32CDF6D-90B4-4CB0-B7C2-F707BD130FB4</gtr:id><gtr:title>Core Outcome Set-STAndards for Reporting: The COS-STAR Statement.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a17f519190d217d4e666d854dbdf4787"><gtr:id>a17f519190d217d4e666d854dbdf4787</gtr:id><gtr:otherNames>Kirkham JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>58a313cfeb37e9.70129364</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K025635/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>E4AF608A-CDB6-4CE6-AA10-95B3E043E22F</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>8.1  Organisation and delivery of services</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>